A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by HotSpot Therapeutics, Inc, active and no longer recruiting.
Overview
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody is a phase 1/2 interventional study registered as NCT05662397 by HotSpot Therapeutics, Inc, with 77 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: HST-1011 and Cemiplimab.
Similar pages
not linked directly; found by shared links- TrialA Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Shares Cemiplimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Shares Cemiplimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTHIO Sequenced With Cemiplimab in Advanced NSCLC
Shares Cemiplimab and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.